Under behandling med Rapamune bør patienter, som får en HMG- CoA reduktase- hæmmer og/ eller fibrat, kontrolleres for mulig udvikling af rhabdomyolyse eller andre bivirkninger, som er beskrevet i de respektive produktresuméer for disse stoffer.
During Rapamune therapy, patients administered an HMG-CoA reductase inhibitor and/ or fibrate, should be monitored for the possible development of rhabdomyolysis and other adverse effects as described in the respective Summary of Product Characteristics of these agents.